Predictors of Ocrelizumab Effectiveness in Patients with Multiple Sclerosis
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Predictors of Ocrelizumab Effectiveness in Patients with Multiple Sclerosis
Authors
Keywords
-
Journal
Neurotherapeutics
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-09-23
DOI
10.1007/s13311-021-01104-8
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Effect of Ocrelizumab in Blood Leukocytes of Patients With Primary Progressive MS
- (2021) José I. Fernández-Velasco et al. Neurology-Neuroimmunology & Neuroinflammation
- Hemophagocytic lymphohistiocytosis associated with ocrelizumab treatment in a patient with multiple sclerosis
- (2021) Agnieszka Machlańska et al. Multiple Sclerosis Journal
- Predicting Infection Risk in Multiple Sclerosis Patients Treated with Ocrelizumab: A Retrospective Cohort Study
- (2021) Nabil Seery et al. CNS DRUGS
- Risk of requiring a walking aid after 6.5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis: Data from the OPERA I and OPERA II trials
- (2021) Gavin Giovannoni et al. EUROPEAN JOURNAL OF NEUROLOGY
- Risk of requiring a wheelchair in primary progressive multiple sclerosis: Data from the ORATORIO trial and the MSBase registry
- (2021) Helmut Butzkueven et al. EUROPEAN JOURNAL OF NEUROLOGY
- Switch from sequestering to anti-CD20 depleting treatment: disease activity outcomes during wash-out and in the first 6 months of ocrelizumab therapy
- (2021) Elisabetta Signoriello et al. Multiple Sclerosis Journal
- Progressive Multifocal Leukoencephalopathy in a Patient With Progressive Multiple Sclerosis Treated With Ocrelizumab Monotherapy
- (2021) Arpan Patel et al. JAMA Neurology
- Ocrelizumab depletes T-lymphocytes more than rituximab in multiple sclerosis
- (2021) Nicola Capasso et al. Multiple Sclerosis and Related Disorders
- Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study
- (2020) Anna He et al. LANCET NEUROLOGY
- Treating multiple sclerosis and neuromyelitis optica spectrum disorder during the COVID-19 pandemic
- (2020) Wallace Brownlee et al. NEUROLOGY
- Real world application of ocrelizumab in multiple sclerosis: Single-center experience of 128 patients
- (2020) Victoria Prockl et al. JOURNAL OF THE NEUROLOGICAL SCIENCES
- Five-years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension
- (2020) Stephen L. Hauser et al. NEUROLOGY
- Initial high-efficacy disease-modifying therapy in multiple sclerosis: A nationwide cohort study
- (2020) Mathias Due Buron et al. NEUROLOGY
- Influenza control during the COVID-19 pandemic
- (2020) Thomas Hills et al. LANCET
- Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial
- (2020) Jerry S Wolinsky et al. LANCET NEUROLOGY
- Real‐world experience of ocrelizumab in multiple sclerosis in a Spanish population
- (2020) Eva Fernandez‐Diaz et al. Annals of Clinical and Translational Neurology
- Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis
- (2019) J. William L. Brown et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis
- (2019) Benjamin Turner et al. JOURNAL OF NEUROLOGY
- Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis
- (2019) Frederik Barkhof et al. NEUROLOGY
- Multiple Sclerosis
- (2018) Daniel S. Reich et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ocrelizumab Depletes CD20+ T Cells in Multiple Sclerosis Patients
- (2018) Stefan Gingele et al. Cells
- Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
- (2017) Stephen L. Hauser et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
- (2017) Xavier Montalban et al. NEW ENGLAND JOURNAL OF MEDICINE
- Features of Human CD3+CD20+T Cells
- (2016) Elisabeth Schuh et al. JOURNAL OF IMMUNOLOGY
- Aggressive multiple sclerosis: proposed definition and treatment algorithm
- (2015) Carolina A. Rush et al. Nature Reviews Neurology
- Rituximab Efficiently Depletes Increased CD20-Expressing T Cells in Multiple Sclerosis Patients
- (2014) Arumugam Palanichamy et al. JOURNAL OF IMMUNOLOGY
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started